Study Title
EZH102: A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Protocol ID
EZH102
Condition/s
Rhabdoid Tumors
INI1-negative Tumors
Synovial Sarcoma
Malignant Rhabdoid Tumor of Ovary
INI1-negative Tumors
Synovial Sarcoma
Malignant Rhabdoid Tumor of Ovary
Diagnosis Stage
Relapse/ refractory
Sponsor
Epizyme, Inc.
Links
Trial Status
Completed
Trial Close Date
22/10/2021
Study Type
Treatment
Phase
Phase 1
Age Eligibility
6 months to 21 years
International registry ID's
NCT02601937
| Study Title | EZH102: A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma |
|---|---|
| Protocol ID | EZH102 |
| Disease (Sub Disease) | Rhabdoid Tumors INI1-negative Tumors Synovial Sarcoma Malignant Rhabdoid Tumor of Ovary |
| Diagnosis Stage | Relapse/ refractory |
| Sponsor | Epizyme, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT02601937 |
| Trial Status | Completed |
| Trial Open Date | 27/05/2016 |
| Trial Close Date | 22/10/2021 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 6 months to 21 years |
| International registry ID's | NCT02601937 |